Rationale The therapeutic potential of monoamine releasers with prominent dopaminergic effects is hindered by their high abuse liability. Objectives The present study examined the effects of several novel Bnorepinephrine (NE)-preferring^monoamine releasers relative to non-selective monoamine releasers, damphetamine and d-methamphetamine, in rhesus monkeys trained to discriminate cocaine. NE-preferring releasers were approximately 13-fold more potent for NE compared to dopamine release and ranged in potency for serotonin release (PAL-329 < l-methamphetamine < PAL-169). Methods Adult rhesus macaques were trained to discriminate 0.4 mg/kg, IM cocaine on a 30-response fixed ratio schedule of food reinforcement. Substitution studies determined the extent to which test drugs produced cocaine-like discriminative stimulus effects and their time course. Drug interaction studies determined whether pretreatment with test drugs altered the discriminable effects of cocaine. Results Results show that cocaine, d-amphetamine, and dmethamphetamine dose-dependently substituted for cocaine with similar potencies. Among the BNE-preferring^releasers, PAL-329 and l-methamphetamine also dose-dependently substituted for cocaine but differed in potency. PAL-169 failed to substitute for cocaine up to a dose that disrupted responding. When administered prior to cocaine, only damphetamine and PAL-329 significantly shifted the cocaine dose-effect function leftward indicating enhancement of cocaine's discriminative stimulus effects. Conclusions These data suggest that greater potency for NE relative to dopamine release (up to 13-fold) does not interfere with the ability of a monoamine releaser to produce cocainelike discriminative effects but that increased serotonin release may have an inhibitory effect. Further characterization of these and other BNE-preferring^monoamine releasers should provide insight into their potential for the management of cocaine addiction.
Introduction
The relative success of agonist, or Bsubstitution,^therapies for the treatment of opioid and nicotine abuse (Wood and Henningfield 1995; Mello and Negus 1996; Grabowski et al. 2004 ) has encouraged the evaluation of candidate medications using this approach for the management of cocaine use disorder. Inasmuch as the abuse-related effects of cocaine can be largely attributed to increased dopamine (DA) neurotransmission (Ritz et al. 1987; Cline et al. 1992 ), most agonist-based candidate medications act, like cocaine, indirectly to increase extracellular DA in the mesolimbic system. For example, damphetamine (d-AMPH) and d-methamphetamine (d-MA), two monoamine releasers with prominent dopaminergic effects (Rothman and Baumann 2003) , can decrease cocaine self-administration without greatly altering other motivated behavior in laboratory animals and human subjects (see Czoty et al. 2016 for review). However, the therapeutic potential of these monoamine releasers is overshadowed by their own abuse liability (Hart et al. 2001; Lile et al. 2013; Kirkpatrick et al. 2012) and their status as Schedule II agents under the Controlled Substances Act.
In view of the potential utility of monoamine releasers for the management of cocaine use disorder, various strategies have been adopted to design effective drugs with reduced abuse potential. For example, considerable attention has focused on the development of novel Bdual^releasers that increase extracellular levels of both DA and serotonin (5-HT). This strategy is predicated on the well-supported idea that increased 5-HT neurotransmission may inhibit DA release and its behavioral sequelae . Indeed, dual DA/5-HT releasers have been shown to attenuate locomotor responses to indirect DA agonists (d-amphetamine, cocaine; Baumann et al. 2011) as well as corresponding increases in extracellular DA in brain regions implicated in their abuse-related effects (Baumann et al. 2011 ); see also (Howell and Cunningham 2015) . Preclinical self-administration studies also support this strategy, showing that monoamine releasers that are non-selective DA/5-HT releasers (e.g., or that release 5-HT selectively (e.g., fenfluramine) are less efficacious reinforcers than drugs that have selective dopaminergic actions (Woods and Tessel 1974; Glowa and Fantegrossi 1997; Wee et al. 2005; . Unfortunately, however, such dual DA/5-HT or 5-HT-selective releasers fail to decrease IV cocaine selfadministration at doses below those that decrease foodmaintained behavior, indicative of a general disruption in motivated behavior (Negus et al. 2007; Banks et al. 2011) . Thus, the ratio of DA to 5-HT activity appears to be an important factor in determining the balance between abuse potential and behavioral selectivity in the effects of monoamine releasers (Negus et al. 2009 ).
In addition to increasing synaptic levels of DA and 5-HT, d-MA and d-AMPH, like cocaine, also can increase synaptic levels of norepinephrine (NE). Although the role of such NErelated actions in the ability of these drugs to reduce cocaine self-administration is unclear (Rothman et al. 2000; Rothman and Baumann 2003; Banks et al. 2014 ), the results of previous studies have shown that alterations in NE activity can modulate behavioral effects of cocaine itself (reviewed by Schmidt and Weinshenker 2014) . For example, NE reuptake inhibitors can substitute for and/or enhance the discriminative stimulus effects of low doses of cocaine in rats and monkeys (Kleven and Koek 1997; Spealman 1995) and partially reinstate extinguished cocaine self-administration in monkeys (Platt et al. 2007 ). Dopamine β-hydroxylase (DβH) inhibition, which decreases neuronal NE and increases extracellular dopamine levels by blocking the conversion of DA to NE, also has been reported to enhance the discriminative stimulus effects of cocaine in rats and to reinstate extinguished cocaine self-administration in monkeys (Manvich et al. 2013; Schroeder et al. 2013) but not rats (Cooper et al. 2014) . Although further work is needed to clarify species-related differences in the neurochemical and behavioral effects of DβH inhibition, it seems evident that modulating NE neuronal activity can directly influence the behavioral effects of cocaine (see also Kohut et al. 2013 ). Moreover, increased or decreased noradrenergic activity alone is not associated with reinforcement, consistent with the low abuse liability of directly or indirectly acting NE-related drugs (Wee and Woolverton 2004; Walsh et al. 2013 ) and supporting the further investigation of candidate medications with prominent noradrenergic actions for cocaine use disorder.
We recently reported that l-MA, like its stereoisomer d-MA, can produce cocaine-like discriminative stimulus effects and selectively reduce the reinforcing effects of cocaine (Kohut et al. 2016) . L-MA is an BNE-preferring^monoamine releaser that, in vitro, is relatively equipotent to d-MA in releasing NE but approximately 15-fold less potent in releasing DA (Rothman and Baumann 2003) . The stereoisomers of MA also release 5-HT with similar potency; however, the relative roles of NE and 5-HT release in the cocaine-like discriminative stimulus effects of l-MA are unclear. The present studies were conducted to examine the contribution of NE and 5-HT release in l-MA's cocaine-like discriminative stimulus effects by evaluating novel BNE-preferring^monoamine releasers with varying potency as 5-HT releasers (PAL-329, l-MA, PAL-169; see Fig. 1 ) in rhesus monkeys trained to discriminate cocaine.
Methods

In vitro monoamine release assay
The potency of d-MA, d-AMPH, PAL-329, l-MA, and PAL-169 to evoke neurotransmitter release via rat monoamine transporters (rSERT, rNET, and rDAT) was determined in rat brain synaptosomes as described previously (Rothman et al. 2000) . 
]NE), the release reaction was terminated by dilution with 4 ml wash buffer (10 mM Tris-HCl pH 7.4 containing 0.9% NaCl at 25°C) followed by rapid vacuum filtration over Whatman GF/B filters and rinsed twice with 4 ml wash buffer using a Brandel Harvester. The retained tritium was counted by a Taurus liquid scintillation counter at 40% efficiency after an overnight extraction in 3 ml Cytoscint (ICN). Non-linear least-squares curve fitting was used to determine EC 50 values (GraphPad Prism, San Diego, CA).
Drug discrimination procedures
Subjects Four cocaine-experienced adult male rhesus monkeys (Macaca mulatta) that weighed between 6 and 10 kg served as subjects. High-protein chow (Purina Monkey Chow, St. Louis, MO) was provided twice daily at least 1 h after experimental sessions supplemented daily with fresh fruit and vegetables. Banana-flavored food pellets (Purina Mills Test Diet, Richmond, IN) were earned during operant sessions. Water was continuously available from an automatic watering system. A 12-h light-dark cycle was in effect (lights on 8:00 a.m. Apparatus All monkeys were housed in stainless-steel chambers (56 × 71 × 69 cm), each equipped with a custom operant response panel (28 × 28 cm) mounted on the front wall. The operant panel included three square translucent response keys (5.1 × 5.1 cm) arranged 3.5 cm apart in a horizontal row 9 cm from the top of the panel. Each key could be transilluminated with red or green stimulus lights (SuperBright LEDs; Fairchild Semiconductor, San Jose, CA). An externally mounted pellet dispenser (model G5210; Gerbrands, Arlington, MA) was attached to the back of the response panel and delivered 1-g banana-flavored food pellets to a receptacle mounted on the front of the cage beneath the response panel. All experimental events were controlled through custom programmed software (Med-PC) on a desktop PC located in a separate room that connected to the chambers via a Med Associates (Georgia, VT) interface.
Discrimination training Monkeys discriminated cocaine (0.4 mg/kg, intramuscularly [IM] ) from saline under a fixed ratio (FR) 30: time-out (TO) 10-s schedule of reinforcement during daily sessions. Training sessions consisted of 1 to 5 cycles, and each cycle included a 15-min time-out period followed by a 5-min response period. Cocaine, or saline, was administered 10 min prior to the onset of each 5-min response period. During the response period, the right and left response keys were illuminated and monkeys could earn up to ten food pellets. Delivery of each pellet was followed by a 10-s timeout, during which response keys were dark and key presses had no programmed consequences. One response key was designated as correct after cocaine injections while the other key was designated as correct following saline injections. The assignment of cocaine and saline keys was counterbalanced across subjects but saline was always associated with green light illumination and drug associated with red lights. A consecutive response contingency was in effect such that pressing the condition-inappropriate key prior to completing the FR30 reset the count toward completion of the response requirement to zero. During training, cocaine was administered only during the final cycle of a session.
The principle dependent variables were (a) percent injection-appropriate responses for the entire cycle, (b) percent injection-appropriate responses prior to the first completed FR30, and (c) response rate in responses/s. Criteria for successful discrimination were (1) at least 80% of total responses before the first completed FR30 on the conditionappropriate key, (2) at least 90% of total responses in each cycle on the stimulus-appropriate key, and (3) rate of responding greater than or equal to 0.2 responses/s. Discrimination testing Once monkeys met criteria for discrimination in each cycle for four consecutive sessions, testing began. Each test session always followed a training session of criterion-level discrimination. Otherwise, training sessions, which consisted of both saline and cocaine cycles, were continued until criterion levels were obtained for at least two consecutive sessions. Test sessions were identical to training sessions except that responding on either key produced food. Two types of studies were conducted: first, substitution studies to determine the extent to which test drugs produced cocaine-like discriminative stimulus effects and their time course and, second, drug interaction studies to determine how pretreatment with test drugs altered the discriminable effects of cocaine. In substitution studies, a single dose of test drug was administered 10 min prior to the first cycle, exactly as in training sessions. Subsequent cycles then began at 30, 60, 100, and 300 min after injection of the test compound or until responding was predominantly on the vehicleappropriate key (i.e., < 20% cocaine-lever responding). In interaction studies, saline and selected doses of test compounds were administered prior to re-determination of the cumulative cocaine dose-effect function (0.032-0.32 mg/kg). Pretreatment times for test compounds were based on data from substitution studies and were the earliest time points at which either full substitution or, in the absence of substitution, decreases in response rate to less than 0.2 responses/s were observed.
Data analysis Cocaine discrimination in test sessions was definedas responding on the cocaine-associated key as a percentage of total responding on both keys, excluding responses during timeouts. The percentage of responding on the cocaineassociated key was not calculated in cases when response rate fell below 0.2 responses/s. Response rates were calculated by dividing the total responses on both keys when the cue lights were illuminated by the total session time and are expressed as responses per second. Data are presented as mean (± SEM) values for the group of monkeys. Substitution test data were interpreted as follows: (1) responding on the cocaine-associated lever below 20% was not considered to deviate significantly from responding engendered by saline, whereas (2) doses of a drug that led to 20-80% cocaine-like responding were considered to partially substitute for the cocaine training dose, and (3) doses of a drug that produced > 80% responding on the cocaine-associated lever were considered to fully substitute for cocaine. Given the 90% accuracy criterion for training session performance, these thresholds can be considered significantly different from chance for a conditional discrimination (Sidman 1980) . ED 80 values, defined as the dose of each test compound that engendered 80% responding on the cocaine-associated lever, were determined using log-linear interpolation with individual subject doseeffect curve data. Log ED 80 values were converted to linear values and corresponding confidence limits (CL) for statistical tests and data presentation. ED 80 was used to determine doses or dose combinations that produced levels of responding indicative of full substitution for the cocaine discriminative stimulus. Shifts in the cocaine dose-effect curve during interaction studies were assessed by comparing relative potency calculated as ED80 Cocaine /ED80 Test compound . Statistical significance was determined by non-overlapping 95% confidence limits for ED 80 values. One-way repeated measures (RM) ANOVA also was used to assess rate-altering effects of each drug or drug combination; further comparisons utilized Dunnett tests, with a criterion significance level of p < 0.05. All statistical tests were conducted with GraphPad Prism software. 
Drugs
Results
In vitro monoamine release Table 1 shows EC 50 values (nM ± SD) for the norepinephrinepreferring releasers, PAL-329, l-MA, and PAL-169 to release Rothman and Baumann 2003 dopamine (DA), norepinephrine (NE), and serotonin (5-HT) in relation to reference compounds, d-AMPH and d-MA. In contrast to d-AMPH and d-MA, which are relatively nonselective dopamine/norepinephrine releasers, each of the NE-preferring releasers was between 13 and 15-fold selective for releasing norepinephrine over dopamine but differed in their selectivity to promote release of 5-HT with a rank order of PAL-329 < l-MA < PAL-169.
Drug discrimination
The training dose of cocaine maintained reliable discriminative control throughout the study. During training sessions that immediately preceded control tests, all subjects responded nearly exclusively on the saline-associated key following saline administration (99% ± 0.66) and on the cocaineassociated key after cocaine administration (99% ± 0.67).
Mean response rates did not differ significantly after treatment with saline or the training dose of cocaine (2.79 ± 0.46 vs. 3.06 ± 0.10 r/s, respectively).
Substitution and time course
Cocaine and the non-selective monoamine releasers, d-AMPH and d-MA, dose-dependently substituted for the training dose of cocaine with similar potencies (full substitution at 0.32 mg/kg, see Table 2 ; Fig. 2 ). Among the BNE-preferring^monoamine releasers, PAL-329 and l-MA also dose-dependently substituted for the training dose of cocaine but varied in potency: PAL-329 was approximately 100-fold less potent than cocaine whereas l-MA was approximately 5-fold less potent (Table 2 ; Fig. 2) . In contrast to the other drugs, PAL-169 failed to substitute for the training dose of cocaine and produced only vehicle lever responding up to a dose (5.6 mg/kg) that decreased rate of responding to below 0.2 responses/s in three of four subjects. PAL-169 was the only monoamine releaser studied that produced decreases in rate of responding within the dose ranges tested (see Fig. 2 , bottom panel). The time course of cocaine-like discriminative stimulus effects varied among drugs. Inspection of group data (Fig. 3, top panels) shows that cocaine and d-AMPH produced maximal cocaine-like responding 10-min after administration of 0.32 mg/kg whereas, consistent with a reportedly slower onset to action in human studies (Newton et al. 2005 ), d-MA produced partial substitution (~75%) at 10 min and full substitution at 30 min after IM administration of 0.32 mg/kg. The BNE-preferring^monoamine releasers PAL-329 and l-MA also engendered full substitution for cocaine at the 10-min time point but differed in their duration of action (Fig. 4, top panels) . A high dose of 18 mg/kg PAL-329 maintained near full cocaine-like responding > 100 min post-injection, with partial substitution still evident at 300 min. The cocaine-like discriminative stimulus effects of 1.0 mg/kg l-MA Table 2 ED 80 estimates (95% C.L.) and relative potency for substitution with peak pretreatment time for cocaine and monoaminergic releasers. dropped to below 80% after the 30-min time point with predominantly vehicle lever responding 100 min after administration. Doses of PAL-169 produced only vehicle lever responding at all time points tested and the rate-altering effects were maintained for > 120 min but returned to baseline by 300 min.
Interaction studies
Control cocaine dose-effect curves (Figs. 5 and 6) and ED 80 analysis reflect averaged data from the first and last control dose-effect curve for all subjects (see above). As in time-course Table 3 ; Fig. 5 ).
The BNE-preferring^drugs varied in their interactive effects with cocaine (Fig. 6) . The highest dose of PAL-329 (10 mg/kg) which, when administered alone produced primarily vehicle-like responding (< 20% cocaine-like responding), significantly shifted the cocaine dose-effect function approximately 3-fold to the left. However, like d-MA, no tested dose of l-MA or PAL-169 significantly altered the position of the cocaine dose-effect function (see Table 3 ). Response rates were not significantly altered by pretreatment with PAL-329, l-MA, or PAL-169 over the range of tested doses, though a modest decrease was evident after 3.2 mg/kg PAL-169 (Fig. 6,  bottom) .
Discussion
The present study was conducted to compare the cocaine-like discriminative stimulus effects of BNE-preferring^mono-amine releasers PAL-329, l-MA, and PAL-169 and nonselective monoamine releasers, d-MA and d-AMPH in rhesus monkeys. Though the three NE-preferring drugs differ in the potency with which they release NE, each exhibit approximately 13-fold greater in vitro potency in releasing NE over DA (Kuczenski et al. 1995; Melega et al. 1999 ; see Table 1 ). Two of the drugs, PAL-329 and l-MA, fully substituted for the training dose of cocaine in the present studies, indicating that their greater potency to release NE over DA (NE/DA ratio) did not interfere with the expression of cocaine-like discriminative stimulus effects, which are thought to involve predominantly dopaminergic actions. The third compound, PAL-169, up to doses that markedly reduced response rates, did not produce any cocaine-like discriminative stimulus effects. In this regard, PAL-169-unlike PAL-329 and l-MA-also exhibits approximately 3-fold greater potency in releasing 5-HT than DA (5-HT/DA ratio). Previous studies have shown that increased 5-HT neurotransmission has an inhibitory effect on extracellular DA-mediated effects Baumann et al. 2011 ) and behavioral studies have described an inverse relationship between the ability of monoamine releasers to produce cocaine-like reinforcing effects and their 5-HT/DA ratio (Glowa and Fantegrossi 1997; Wee et al. 2005) . Thus, it is tempting to suggest that the 5-HT-related actions of PAL-169 may have attenuated its ability to produce cocaine-like discriminative stimulus effects in the present study. However, this suggestion is not supported by previous findings with the related drug PAL-287, which has a 5-HT/DA ratio like that of PAL-169 (PAL-287 EC 50 for DA = 12.6, NE = 11.1, 5-HT = 3.4). In those studies, PAL-287 produced dose-related and full substitution in rhesus monkeys trained to discriminate cocaine from saline (Negus et al. 2007; Banks et al. 2014) . It is noteworthy that, unlike PAL-169 but like d-MA and d-AMPH, PAL-287 releases NE and DA with similar potency. Possibly, behaviorally active doses of PAL-169 produce a combination of prominent NE-mediated and 5-HT-mediated, rather than DA-mediated, actions that preclude the expression of cocaine-like discriminative stimulus effects. It is also possible that some unknown, off-target (i.e., nonmonoaminergic) mechanism may be responsible for this difference.
Both PAL-329 and l-MA were less potent in producing cocaine-like discriminative stimulus effects than d-MA and d-AMPH, (relative potencies approximately 100:5:1:1 for PAL-329:l-MA:d-MA:d-AMPH). Although the rank order of potency is similar to the rank order of their in vitro potencies for releasing DA and NE, there is limited correspondence between relative potencies for producing cocaine-like discriminative stimulus effects and, based on EC 50 values, relative Tables 1 and 2 ). It also is interesting to note that NEpreferring and non-selective monoamine releasers appeared to differ in their ability to produce partial (20-80%) substitution for cocaine when administered alone. For example, doses of PAL-329 and l-MA below those that produced full substitution failed to engender > 20% responding on the cocaineassociated key whereas 0.01 mg/kg of d-MA or d-AMPH produced partial (approximately 50%) substitution for the training dose of cocaine. It may be that the NE-related actions of PAL-329 and l-MA predominated until the dose was sufficiently high to reach a Bthreshold^level of DA release (Desai and Bergman 2010; Kohut et al. 2014) . Interestingly, previous findings in squirrel monkeys have shown that norepinephrine reuptake inhibitors substitute for the discriminative stimulus effects of a low, but not high, cocaine training dose (Spealman 1995) suggesting that the substitution profile of these compounds may change with a higher or lower training dose than that used in the present study. Additional research is necessary to determine whether differences in time course or maximal increase in extracellular neurotransmitter levels may account for the differences in substitution profile.
The present studies indicate that d-AMPH accentuates the discriminative stimulus effects of cocaine. Previous studies in rodents, on the other hand, have found that both d-MA and d-AMPH produced leftward shifts in the dose-effect function for cocaine discrimination that were greater than predicted by simple addition (Li et al. 2006 ). Such differences in drug interactions may be the result of species-related differences in monoamine systems that have been reported previously. Alternatively, these findings may reflect differences in the relative potency of the drugs in the two sets of studies. In contrast to their similar potencies in monkeys shown in the present study, d-MA and d-AMPH were more potent than cocaine in rodents-a difference that, in turn, may be attributable to dissimilar training doses of cocaine (3 or 10 mg/kg, IP rat, Terry et al. 1994 ; 0.4 mg/kg, IM monkey, present study). The NE-preferring monoamine releaser PAL-329 produced a significant leftward shift in the cocaine dose-effect function. Doses of PAL-329 that engendered < 20% cocaine-like responding when administered alone produced a 50% or greater increase in cocaine-like responding when combined with low and intermediate doses of cocaine which had little effect alone. On the other hand, PAL-169 or l-MA did not appreciably modify cocaine's discriminative stimulus effects. As discussed above, PAL-169 failed to produce cocaine-like discriminative stimulus effects, andit is not surprisingthat it alsofailed to accentuate those of cocaine itself. However, the difference in the modification of cocaine's effects by PAL-329 and l-MA is somewhat surprising. It is possible that the difference in their potencies for releasing 5-HT was a contributing factor, i.e., cocaine-like effects produced by the release of NE and DAwere more effectively dampened by the serotonergic activity of l-MA than PAL-329. In this regard, it is noteworthy that the only other leftward shifts in the cocaine dose-effect function in the interaction studies occurred after d-AMPH which, like PAL-329, has negligible activity as a 5-HT releaser, and may help to explain the absence of a shift following d-MA which has a 5-HT/DA EC 50 ratio more similar to l-MA. However, the role of 5-HT in such drug interactions remains speculative in the absence of additional comparison data.
We have previously reported that l-MA is about 3-5-fold less potent than d-MA in rats or monkeys trained to discriminate either cocaine or d-MA (Yasar and Bergman 1994; Desai and Bergman 2010; Kohut et al. 2016 ). The present studies add to these results showing that l-MA also has a shorter duration of cocaine-like effects than d-MA. These observations are consistent with previous studies indicating that the subjective effects of l-MA disappear more quickly than those of d-MA (Mendelson et al. 2006 ) and the shorter duration of l-MA's cocaine-like effects do not appear to be related to large differences in pharmacokinetics of the two isomers. PET studies in baboons have shown a similar time course of distribution in various brain regions following their intravenous administration (Fowler et al. 2007 ). On the other hand, a pharmacokinetic comparison of d-and l-MA in human subjects found that metabolism of MA is stereoselective (Li et al. 2010) . Differences in the bioactivity of d-MA or l-MA metabolites, in turn, may contribute to differences in the time course of the behavioral effects resulting from administration of the two isomers of methamphetamine.
Finally, it may be useful to consider the present findings within the framework of agonist-type medications for the management of cocaine use disorder (Kohut et al. 2016) . The agonist replacement approach to medication development is intended to identify compounds with biochemical and behavioral effects that overlap those of cocaine, presumably easing abnormalities in brain chemistry and function that have been characterized in long-term drug abusers . Overlapping behavioral effects also may encourage compliance with the medication regimen, a key factor in treatment outcomes. In the present experiments, two monoamine releasers, l-MA and PAL-329, were shown to produce cocaine-like discriminative stimulus effects in monkeys, suggesting that they meet the above criteria. One of these compounds, l-MA, also has been shown to serve as a positive reinforcer in rodents (Yokel and Pickens 1973) and monkeys (Winger et al. 1994) , further confirming the overlap with behavioral effects of cocaine. Both compounds also exhibit an approximately 15-fold greater potency in releasing NE than DA, which may be therapeutically advantageous. For example, the subjective effects of l-MA in human studies are similar in some respects to those of d-MA. However, the subjective effects of the two isomers also differ in potentially important ways. While both l-MA and d-MA produce subjective ratings of Bdrug liking^and Bgood effects^in experienced stimulant users, only l-MA produces concomitant ratings of bad or aversive drug effects (Mendelson et al. 2006 ), a factor which may limit its abuse liability. It is important to note that both Mendelson et al. (2006) and the present study only included male subjects and it will be important for future studies to extend these findings to female subjects to determine whether sex as a biological variable influences responses to monoamine releasers. Regardless, it is tempting to suggest that the differences in the behavioral effects of the two isomers can be attributed to differences in their relative potencies for releasing NE and DA. However, it also is possible that the dissimilar behavioral profiles reflect differences in potency of drugs like d-MA and d-AMPH (high) and l-MA and PAL-329 (low) for releasing DA. Further characterization of these and additional compounds with similar pharmacological profiles as BNEpreferring^monoamine releasers varying in potency for releasing DA should provide insight into the mechanism of their behavioral effects and, as well, their value for the management of cocaine use disorder.
